Article Text

Download PDFPDF

Recombinant tissue plasminogen activator following paediatric cataract surgery
  1. J S Mehta,
  2. G G W Adams
  1. Strabismus and Paediatric Service, Moorfields Eye Hospital, London
  1. Dr J S Mehtajodmehta{at}hotmail.com

Abstract

BACKGROUND The use of recombinant tissue plasminogen activator (r-TPA) has been advocated in the treatment of postsurgical fibrinous membrane formation following cataract surgery in adults. Its use in paediatric cases is not well documented.

METHOD A retrospective review of paediatric cataract extractions performed at Moorfields Eye Hospital between 1 January 1997 and 4 April 1999 was carried out.

RESULTS Cataract extractions were performed in 37 patients, 22 in males 15 in females. Four (9.2%) underwent intracameral injection of 25 μg r-TPA. They were all females of Afro-Caribbean origin. The time to injection varied from 4–14 days, mean 7.2 days. Complete resolution of the fibrinous membrane was seen in all cases. There were no complications by the 3 month follow up.

CONCLUSION r-TPA may be used safely and effectively at a dose of 25 μg for the treatment of severe fibrinous membranes following paediatric cataract extraction. It aided the visual recovery of the children and also allowed a reduced regimen of topical steroid therapy to be used postoperatively.

  • recombinant tissue plasminogen activator
  • paediatrics
  • cataract
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.